Genevant Sciences

Our proprietary LNP and conjugate technologies deliver your nucleic acid to the target tissue. We transform your payload into a potential new medicine and support you into and through the clinic. Reach out to Dmytro Kukhtar to learn how. #BIO2026 #invivoCART #NucleicAcid #LNP #Conjugate #GeneTherapy

Genevant is committed to driving and supporting innovation in the gene therapy space.   We’re proud to sponsor the ASGCT 2026 Annual Meeting, taking place May 11-15 in Boston.   #ASGCT2026 #LNP #GeneTherapy

Conference season is here. The Genevant team will be part of three major events in the coming months:   🇨🇭 𝐒𝐰𝐢𝐬𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐃𝐚𝐲 2026 — Basel | May 3–5 🇺🇸 𝐀𝐒𝐆𝐂𝐓 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 2026 — Boston | May 11–15 🇺🇸 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 2026 — San Diego | June 22–25   Let's connect!   #LNP #GeneTherapy #ASGCT2026 #SwissBiotechDay #BIO2026

Do not miss the presentation by our CTO, Ed Yaworski, at the upcoming Swiss Biotech Day to learn more about our LNP delivery platform and how we can support your genetic medicine programs for hepatic or extrahepatic applications. 📅 Monday, May 4 at 3:30 pm CET | 📍 Room Montreal, Level 2 You can also find us at our exhibitor booth 99! #LNP #GeneticMedicine #swissbiotechday #swissbiotech #biotech #lifesciences #basel #switzerland

Genevant is proud to sponsor #CRISPRMED26 organized by CRISPR Medicine News on April 13-16 in Copenhagen. If safe, effective and tissue-specific nucleic acid delivery stands between you and clinical and commercial success for a new genetic medicine, reach out to Dmytro Kukhtar to learn how we can help! #GeneEditing #LNP #CRISPR

Our team is exhibiting at #BIOEuropeSpring 2026! You will find us at Exhibition Booth 14. We are looking forward to connecting with you. 📅 Mar 23-25 | 📍Lisbon, Portugal #LNP #RNA #mRNA #genetherapy #invivoCART

Yesterday, we and our licensor Arbutus Biopharma Corporation announced a $2.25B global settlement of our patent litigation with Moderna related to its COVID-19 vaccines, whereby Moderna will pay $950M upfront and an additional $1.3B contingent upon resolution of Moderna’s Section 1498 appeal favorable to us. As our CEO James Heyes said, the settlement allows us to remain focused on our mission to leverage our world-class nucleic acid delivery systems to bring innovative medicines to people who need them while also recognizing the pivotal contribution that the Genevant team made to restoring normalcy in the face of a once-in-a-lifetime pandemic.     We are thrilled to see inventors Ian MacLachlan, Ed Yaworski, Lloyd Jeffs, Kieu Lam, Lorne Palmer, and the late Cory Giesbrecht get the recognition they so richly deserve.   We encourage you to read our press release for additional detail. https://lnkd.in/epXgckTN

Yesterday, we and our licensor Arbutus Biopharma Corporation announced a $2.25B global settlement of our patent litigation with Moderna related to its COVID-19 vaccines, whereby Moderna will pay $950M upfront and an additional $1.3B contingent upon resolution of Moderna’s Section 1498 appeal favorable to us. As our CEO James Heyes said, the settlement allows us to remain focused on our mission to leverage our world-class nucleic acid delivery systems to bring innovative medicines to people who need them while also recognizing the pivotal contribution that the Genevant team made to restoring normalcy in the face of a once-in-a-lifetime pandemic.     We are thrilled to see inventors Ian MacLachlan, Ed Yaworski, Lloyd Jeffs, Kieu Lam, Lorne Palmer, and the late Cory Giesbrecht get the recognition they so richly deserve.   We encourage you to read our press release for additional detail. https://lnkd.in/epXgckTN

After a great #BioEurope, Genevant is now at the #mRNAHealthConference! Our CTO, Ed Yaworski, presented our latest advances and how we can help your company succeed. Ed Yaworski, Tracy Meffen, Dmytro Kukhtar

The Genevant Sciences team is excited to sponsor and participate in the 13th Annual mRNA Health Conference! We look forward to connecting with fellow leaders and innovators in the mRNA space.   Be sure to join the presentation by our CTO, Ed Yaworski, on November 12th at 9:50. He will discuss how Genevant is Innovating the Delivery of Next-Generation Nucleic Acid Therapeutics.   If you're attending and want to discuss how our LNP delivery platform can help your programs succeed, please send us a direct message to arrange a meeting or come by our booth!   #Genevant #mRNA #mRNAHealthConference #LNP #LipidNanoparticles #DrugDelivery #Biotech